Patents by Inventor Geoffrey Guy

Geoffrey Guy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11941867
    Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for training a classification neural network.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: March 26, 2024
    Assignee: Google LLC
    Inventors: Geoffrey E. Hinton, Nicholas Myles Wisener Frosst, Nicolas Guy Robert Papernot
  • Publication number: 20240091241
    Abstract: The present invention relates to the use of a cannabidiol (CBD) preparation in the treatment of temporal lobe epilepsy. In particular the CBD preparation is characterized by chemical components and/or functional properties that distinguish them from prior CBD compositions. Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-Cl at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used.
    Type: Application
    Filed: October 23, 2020
    Publication date: March 21, 2024
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Patent number: 11922729
    Abstract: Commercial interactions with non-discretized items such as liquids in carafes or other dispensers are detected and associated with actors using images captured by one or more digital cameras including the carafes or dispensers within their fields of view. The images are processed to detect body parts of actors and other aspects therein, and to not only determine that a commercial interaction has occurred but also identify an actor that performed the commercial interaction. Based on information or data determined from such images, movements of body parts associated with raising, lowering or rotating one or more carafes or other dispensers may be detected, and a commercial interaction involving such carafes or dispensers may be detected and associated with a specific actor accordingly.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: March 5, 2024
    Assignee: Amazon Technologies, Inc.
    Inventors: Kaustav Kundu, Pahal Kamlesh Dalal, Nishitkumar Ashokkumar Desai, Jayakrishnan Kumar Eledath, Geoffrey A. Franz, Gerard Guy Medioni, Hoi Cheung Pang, Rakesh Ramakrishnan
  • Publication number: 20240033229
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Application
    Filed: February 16, 2023
    Publication date: February 1, 2024
    Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Anne COMI
  • Patent number: 11865102
    Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(IR,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: January 9, 2024
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
  • Publication number: 20230301936
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: May 19, 2023
    Publication date: September 28, 2023
    Inventors: Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
  • Patent number: 11766411
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: September 26, 2023
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11752111
    Abstract: The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: September 12, 2023
    Assignee: GW RESEARCH LIMITED
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo, Joanna Neill
  • Publication number: 20230263744
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a Cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form.
    Type: Application
    Filed: May 2, 2023
    Publication date: August 24, 2023
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Livio Luongo
  • Publication number: 20230248664
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 20, 2023
    Publication date: August 10, 2023
    Inventors: Geoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
  • Patent number: 11701330
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: July 18, 2023
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11679087
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a Cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 20, 2023
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Livio Luongo
  • Patent number: 11633369
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: April 25, 2023
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Publication number: 20230068885
    Abstract: The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.
    Type: Application
    Filed: June 15, 2022
    Publication date: March 2, 2023
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Eduardo DUNAYEVICH, David CRITCHLEY
  • Patent number: 11590087
    Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidivarin (6-OH CBDV), is a metabolite of cannabidivarin (CBDV). The cannabinoid can be produced by synthetic means and a method for the production of 6-OH CBDV is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-OH CBDV in a model of disease.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: February 28, 2023
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts
  • Publication number: 20230032502
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of of nocturnal snoring. In particular the CBD appears particularly effective in treating nocturnal snoring in children and young adults with epilepsy The disclosure further relates to the use of CBD in 5 combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 28, 2022
    Publication date: February 2, 2023
    Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Orrin DEVINSKY
  • Publication number: 20230026079
    Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.
    Type: Application
    Filed: November 18, 2020
    Publication date: January 26, 2023
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20230022487
    Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C1 (CBD-C1), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the 5 cannabinoid can be produced by synthetic means and a method for the production of CBD-C1 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C1 in models of disease.
    Type: Application
    Filed: November 18, 2020
    Publication date: January 26, 2023
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20230000789
    Abstract: The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidiol (6-0 H CBD), is a metabolite of CBD. The cannabinoid can be produced by synthetic means and a method for the production of 6-0 H CBD is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-0 H CBD in a model of disease.
    Type: Application
    Filed: November 18, 2020
    Publication date: January 5, 2023
    Inventors: Geoffrey GUY, Volker KNAPPERTZ, Benjamin WHALLEY, Marie WOOLLEY-ROBERTS
  • Publication number: 20220395471
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: August 11, 2022
    Publication date: December 15, 2022
    Inventors: Geoffrey GUY, Stephen Wright, Orrin Devinsky